CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

Memorial Sloan Kettering, New York

North Shore Hematology Oncology Associates, East Setauket

Maryland Oncology Hematology, Silver Spring

Virginia Oncology Associates, Norfolk

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

Duke University, Durham

Novant Health Presbyterian Medical Center - Oncology Research, Charlotte

Charleston Hematology and Oncology Associates, Charleston

Georgia Cancer Center at Augusta University, Augusta

Florida Cancer Specialists- North, St. Petersburg

Florida Cancer Specialists, Fort Myers

Wallace Tumor Institute- University of Alabama, Birmingham

Clearview Cancer Institute, Huntsville

SCRI Tenessee Oncology Nashville, Nashville

Precision Cancer Research/Brig Center for Cancer Care and Survivorship, LLC, Knoxville

University of Louisville Hospital / James Brown Cancer Center, Louisville

The Ohio State University, Columbus

Gabrail Cancer Center Research, Canton

Oncology Hematology Care, Inc, Cincinnati

University of Michigan, Ann Arbor

Henry Ford Hospital, Detroit

Masonic Cancer Center, Minneapolis

SCRI - HCA Midwest Division, Kansas City

Cancer Network/Oncology Associates PC, Omaha

Nebraska Cancer Specialists, Omaha

Stephenson Cancer Center, Oklahoma City

Mary Crowley Cancer Research Centers, Dallas

The University of Texas Southwestern Medical Center, Dallas

The Center for Cancer and Blood Disorders (Fort Worth), Fort Worth

US Oncology, Fort Worth

University of Colorado, Aurora

Rocky Mountain Cancer Centers, Lakewood

Huntsman Cancer Institute, Salt Lake City

OHSU Knight Cancer Institute, Portland

Massachusetts General Hospital, Boston

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack